<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027832</url>
  </required_header>
  <id_info>
    <org_study_id>102/09</org_study_id>
    <nct_id>NCT01027832</nct_id>
  </id_info>
  <brief_title>Antibiotic Treatment in Ventilator Associated Tracheobronchitis (VAT)</brief_title>
  <official_title>Antibiotic Treatment in Ventilator Associated Tracheobronchitis (VAT): A Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mechanically Ventilated patients in the intensive care unit (ICU) often present with fever,
      and purulent sputum, but without radiological evidence of pneumonia.

      These patients may have tracheobronchitis. Some suspect that this condition precedes the
      development of pneumonia. Antibiotic treatment in tracheobronchitis is controversial.

      The investigators will recruit patients with tracheobronchitis and randomize them into 2
      groups. One group will be treated with antibiotics and the other group will serve as control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with proved tracheobronchitis who are mechanically ventilated for more than 48 hrs,
      will undergo a CT scan to rool our pneumonia that may not be seen on a routine chest x-ray.

      After ruling out pneumonia by CT scan, patients will be randomized into 2 groups.
      Intervention group will receive 7 days of treatment with Piperacillin/Tazobactam. A control
      group will receive nothing.

      Primary endpoint wil be the rate of new pneumonias and secondary endpoint will be ICU Length
      of stay, days on mechanical ventilation and 28 day mortality.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of development of new pneumonia</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay (LOS) and mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Tracheobronchitis</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/Tazobactam for 7 days</intervention_name>
    <description>Piperacillin/Tazobactam for 7 days</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Tracheobronchitis as defined by:

               -  Purulent sputum with &gt; 10 x 4 CFU

               -  Leukocytosis or leukopenia

               -  Fever

               -  No pneumonia on CT scan

        Exclusion Criteria:

          -  Recent treatment of pneumonia

          -  Abnormal Chest X-ray

          -  Evidence of Pneumonia on CT scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arie Soroksky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv University, Faculty of Medicine, Israel.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arie Soroksky, MD</last_name>
    <phone>972-8-9779320</phone>
    <email>soroksky@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assaf Harofe MC</name>
      <address>
        <city>Beer Yakov</city>
        <state>Zerifin</state>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arie Soroksky, M.D.</last_name>
      <phone>972-8-9779320</phone>
      <email>soroksky@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Arie Soroksky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <last_update_submitted>December 8, 2009</last_update_submitted>
  <last_update_submitted_qc>December 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Arie Soroksky M.D.</name_title>
    <organization>AGeneral ICU, Assaf Harofe MC, Zerifin 70300, Israel</organization>
  </responsible_party>
  <keyword>tracheobronchitis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

